Shares of PI Industries were down 8 per cent to Rs 2,756 on the BSE in Tuesday’s intra-day trade after the company terminated the agreement related to acquisition on slump sale of Ind-Swift Laboratories (ISLL). This is due to ISLL has not been able to complete several of the pre-agreed conditions precedents.

“Given non-fulfilment and also disagreement on some of the pre-agreed conditions, the company has decided not to pursue the transaction further,” PI Industries said in a statement.

• NBD Bank Gets Nod from Central Bank to Acquire Stake in RBL Bank
• LIC Gets Slammed with Rs 6,146 Crore Tax Demand
• L&T Tech Planning to Sell its Unit to AMI Paradigm Solutions
• LNG Buyers Turn to US as Qatar Supply Disrupts
• Iran Plans Transit Tolls on Strait of Hormuz

PIs’ strategy to strengthen presence in custom synthesis exports through diversification into adjacencies, including pharma, remains intact. The R&D establishment within PI remains attuned to developing and scaling multiple advanced technologies, processes, and platforms to execute its long-term strategy, the company said. “PI Industries will continue to evaluate other M&A opportunities that are aligned to it strategic direction with the intention to create a differentiated scale play in pharma,” it added.